Firm settles FTC charges
This article was originally published in The Tan Sheet
Executive Summary
An FTC order directs Sagee U.S.A. Group to pay $10,000 in redress to settle charges of making false and unsubstantiated claims for its eponymous product. The order includes a $1.38 mil. avalanche clause that would be put into effect if the firm misrepresents its financial state. Original claims stated that Sagee could improve brain health, revitalize and rejuvenate the brain and alleviate or treat a number of serious, chronic brain-related diseases, including schizophrenia, Alzheimer's and Parkinson's disease. The firm advertised the supplement through radio, TV, print and internet media to the Chinese and Vietnamese-speaking communities. The order also requires various recordkeeping provisions to aid FTC in future monitoring the firm's compliance...
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.